Header

UZH-Logo

Maintenance Infos

Publications for Arnold, J J

Navigate back| Up a level
Export as
Group by:
Number of items: 14.

2017

Vaze, Anagha; Nguyen, Vuong; Daien, Vincent; Arnold, Jennifer J; Young, Stephanie H; Cheung, Chui M; Lamoureux, Ecosse; Bhargava, Mayuri; Barthelmes, Daniel; Gillies, Mark C; Fight Retinal Blindness Study Group (2017). Ranibizumab and Aflibercept for the Treatment of Pigment Epithelial Detachment in Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Retina:Epub ahead of print.

Barthelmes, Daniel; Nguyen, Vuong; Daien, Vincent; Campain, Anna; Walton, Richard; Guymer, Robyn; Morlet, Nigel; Hunyor, Alex P; Essex, Rohan W; Arnold, Jennifer J; Gillies, Mark C; Fight Retinal Blindness Study Group (2017). Two Year Outcomes of "Treat And Extend" Intravitreal Therapy Using Aflibercept Preferentially for Neovascular Age-Related Macular Degeneration. Retina:Epub ahead of print.

2016

Barthelmes, Daniel; Campain, Anna; Nguyen, Phuc; Arnold, Jennifer J; McAllister, Ian L; Simpson, Judy M; Hunyor, Alex P; Guymer, Robyn; Essex, Rohan W; Morlet, Nigel; Gillies, Mark C; Fight Retinal Blindness! Project Investigators (2016). Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. The British Journal of Ophthalmology, 100(12):1640-1645.

Gillies, Mark C; Nguyen, Vuong; Daien, Vincent; Arnold, Jennifer J; Morlet, Nigel; Barthelmes, Daniel (2016). Twelve-month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: data from an observational study. Ophthalmology, 123(12):2545-2553.

Essex, Rohan W; Nguyen, Vuong; Walton, Richard; Arnold, Jennifer J; McAllister, Ian L; Guymer, Robyn H; Morlet, Nigel; Young, Stephanie; Barthelmes, Daniel; Gillies, Mark C; Fight Retinal Blindness Study Group (2016). Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration. Ophthalmology, 123(11):2393-2400.

2015

Gillies, Mark C; Campain, Anna; Barthelmes, Daniel; Simpson, Judy M; Arnold, Jennifer J; Guymer, Robyn H; McAllister, Ian L; Essex, Rohan W; Morlet, Nigel; Hunyor, Alex P (2015). Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology, 122(9):1837-1845.

Arnold, Jennifer J; Campain, Anna; Barthelmes, Daniel; Simpson, Judy M; Guymer, Robyn H; Hunyor, Alex P; McAllister, Ian L; Essex, Rohan W; Morlet, Nigel; Gillies, Mark C (2015). Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology, 122(6):1212-1219.

Barthelmes, D; Walton, R; Campain, A E; Simpson, J M; Arnold, J J; McAllister, I L; Guymer, R H; Hunyor, R H; Essex, R W; Morlet, N; Gillies, M C (2015). Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. The British Journal of Ophthalmology, 99(3):359-364.

Gillies, M C; Campain, A; Walton, R; Simpson, J M; Arnold, J J; Guymer, R H; McAllister, I L; Hunyor, A P; Essex, R W; Morlet, N; Barthelmes, D (2015). Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab. Ophthalmology, 122(3):589-594.e1.

2014

Gillies, M C; Walton, R J; Arnold, J J; McAllister, I L; Simpson, J M; Hunyor, A P; Guymer, R; Essex, R W; Moriet, N; Barthelmes, D (2014). Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. Ophthalmology, 121(3):676-681.

Gillies, M C; Walton, R; Liong, J; Arnold, J J; McAllister, I; Morlet, N; Hunyor, A; Guymer, R; Keeffe, J; Essex, R; Herrera-Bond, A; Glastonbury, B; Simpson, J M; Barthelmes, D (2014). Efficient capture of high-quality data on outcomes of treatment for macular diseases: The Fight Retinal Blindness! Project. Retina, 34(1):188-195.

O'Day, Roderick F; Barthelmes, Daniel; Zhu, Meidong; Wong, Tien Y; McAllister, Ian L; Arnold, Jennifer J; Gillies, Mark C (2014). Intraocular pressure rise is predictive of vision improvement after intravitreal triamcinolone acetonide for diabetic macular oedema: a retrospective analysis of data from a randomised controlled trial. BMC Ophthalmology, 14:123.

Barthelmes, D; Walton, R J; Arnold, J J; McAllister, I L; Simpson, J M; Campain, A; Hunyor, A P; Guymer, R; Essex, R W; Morlet, N; Gillies, M C (2014). Intravitreal Therapy in Bilateral Neovascular Age-Related Macular Degeneration. Ophthalmology, 121(10):2073-2074.

2013

O'Day, R; Barthelmes, D; Zhu, M; Wong, T Y; McAllister, I L; Arnold, J J; Gillies, M C (2013). Baseline central macular thickness predicts the need for retreatment with intravitreal triamcinolone plus laser photocoagulation for diabetic macular edema. Clinical Ophthalmology, 7:1565-1570.

This list was generated on Tue Nov 21 13:48:02 2017 CET.